Nasdaq
$4.01▲ 0.02%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $398.3MShares out 99.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
20- 5d agoAfter-hours26.10.20 05:22144Ownership#●●●#●●●
ARS Pharmaceuticals, Inc.
Eric Karas, an insider at ARS Pharmaceuticals, has filed an SEC Form 144 to report a proposed sale of company shares. This is a standard filing disclosing the insider's plan to dispose of their holdings.…more
$4.01+0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:244Ownership
ARS Pharmaceuticals, Inc.
Insider Casale Donn of ARS Pharmaceuticals reported a change in beneficial ownership of company securities as of October 1, 2026. This filing serves as a formal notification of the insider's transaction via Form 4.…more
$4.01+0.02%vs prev closeView filingShare - 10.1After-hours26.10.02 05:29144Ownership
ARS Pharmaceuticals, Inc.
Eric Karas, an insider at ARS Pharmaceuticals, has filed an SEC Form 144 to report a proposed sale of company shares. This is a standard filing disclosing an insider's plan to dispose of their holdings.…more
$4.01+0.02%vs prev closeView filingShare
19 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.1After-hours26.09.02 05:01#●●●#●●●
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
ARS Pharmaceuticals announced that its CEO will participate in upcoming investor conferences hosted by Wells Fargo and Cantor Fitzgerald in September. This announcement serves as a routine investor relations update and does not contain material financial news.…more
$4.01+0.02%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.13After-hours26.08.14 05:01
●●●●●●●● ●●●●● ●●●●●●
ARS Pharmaceuticals is shifting its commercial strategy to target healthcare providers and implementing cost-cutting measures to reach cash flow breakeven by the end of 2027. The company is also advancing its intranasal epinephrine platform into chronic spontaneous urticaria with interim data expected in early 2027.…more
$4.01+0.02%vs prev close - 8.3Pre-market26.08.03 20:30
●●●●●●●● ●●●●● ●●●●●●
ARS 파마슈티컬스가 오는 8월 13일 컨퍼런스 콜을 통해 2분기 실적과 함께 회사의 업데이트된 전략적 우선순위를 공개할 예정이다. 신임 CEO 체제 하에서 발표되는 이번 전략 방향이 향후 주가 흐름에 중요한 변수가 될 전망이다.…more
$4.01+0.02%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report